Daniel B Chastain1, Andrés F Henao-Martínez2, Carlos Franco-Paredes2,3. 1. University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA, 31701, USA. daniel.chastain@uga.edu. 2. University of Colorado Denver, Anschutz Medical Campus, Denver, CO, USA. 3. Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico.
Abstract
PURPOSE OF REVIEW: The goal of this review is to provide an update on the epidemiology, diagnosis, and treatment of opportunistic fungal infections in patients with human immunodeficiency virus (HIV) infection including Cryptococcus spp., Histoplasma spp., Coccidioides spp., and Talaromyces marneffei, formerly Penicillium marneffei. RECENT FINDINGS: In many settings, despite increasing roll out of antiretroviral therapy (ART), opportunistic invasive mycoses produce a substantial burden of disease. The prevalence of specific fungal pathogens depends on their endemicity. Viral suppression achieved by greater access to ART and increased the availability of point-of-care testing with rapid diagnostic tests (RDTs) aid to curtail the associated fungi morbidity. RDTs allow earlier screening to preemptively initiate treatment of opportunistic fungal pathogens. Identifying asymptomatic cryptococcal infection before starting ART is crucial in reducing the risk of the immune reconstitution inflammatory syndrome (IRIS). There is an urgent need to decrease the burden of opportunistic invasive fungal infections in individuals with HIV/AIDS through different interventions: (a) continue to expand the deployment of ART to the most affected populations to achieve viral suppression; (b) ensure early diagnosis of fungal pathogen with point-of-care testing; (c) improve fungal diagnostic capacity in areas with the highest burden of AIDS-related mycoses; and (d) increased availability of existing antifungal drugs to optimally treat these infections.
PURPOSE OF REVIEW: The goal of this review is to provide an update on the epidemiology, diagnosis, and treatment of opportunistic fungal infections in patients with human immunodeficiency virus (HIV) infection including Cryptococcus spp., Histoplasma spp., Coccidioides spp., and Talaromyces marneffei, formerly Penicillium marneffei. RECENT FINDINGS: In many settings, despite increasing roll out of antiretroviral therapy (ART), opportunistic invasive mycoses produce a substantial burden of disease. The prevalence of specific fungal pathogens depends on their endemicity. Viral suppression achieved by greater access to ART and increased the availability of point-of-care testing with rapid diagnostic tests (RDTs) aid to curtail the associated fungi morbidity. RDTs allow earlier screening to preemptively initiate treatment of opportunistic fungal pathogens. Identifying asymptomatic cryptococcal infection before starting ART is crucial in reducing the risk of the immune reconstitution inflammatory syndrome (IRIS). There is an urgent need to decrease the burden of opportunistic invasive fungal infections in individuals with HIV/AIDS through different interventions: (a) continue to expand the deployment of ART to the most affected populations to achieve viral suppression; (b) ensure early diagnosis of fungal pathogen with point-of-care testing; (c) improve fungal diagnostic capacity in areas with the highest burden of AIDS-related mycoses; and (d) increased availability of existing antifungal drugs to optimally treat these infections.
Authors: Joseph N Jarvis; Ann Percival; Sean Bauman; Joy Pelfrey; Graeme Meintjes; G Ntombomzi Williams; Nicky Longley; Thomas S Harrison; Thomas R Kozel Journal: Clin Infect Dis Date: 2011-09-21 Impact factor: 9.079
Authors: Neil French; Katherine Gray; Christine Watera; Jessica Nakiyingi; Eric Lugada; Michael Moore; David Lalloo; James A G Whitworth; Charles F Gilks Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Amaury Dos Santos Bentes; Bodo Wanke; Márcia Dos Santos Lazéra; Ana Karla Lima Freire; Roberto Moreira da Silva Júnior; Diego Fernando Silva Rocha; Silviane Bezerra Pinheiro; Steven Edward Zelski; Ani Beatriz Jackisch Matsuura; Liliane Coelho da Rocha; Erica Simplício de Souza; João Vicente Braga de Souza Journal: Braz J Microbiol Date: 2019-03-09 Impact factor: 2.476
Authors: Linh Vu Phuong Dang; Quan Hai Nguyen; Azumi Ishizaki; Mattias Larsson; Nhung Thi Phuong Vu; Cuong Do Duy; Linus Olson; Thanh Thi Dinh Journal: Am J Mens Health Date: 2020 May-Jun